About

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Its product development is organized into three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of progress. Retro Biosciences utilizes advanced technologies like single-cell multi-omics and computational biology to enhance its research and development efforts. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases by focusing on aging itself rather than treating individual conditions. The company's goal is to reduce healthcare expenses associated with age-related diseases while improving the quality of life for individuals as they age.

Simplify's Take

What believers are saying

• Retro Biosciences secured $180 million funding, supporting operations and research for a decade.
• Partnership with Multiply Labs enhances cost-efficient, scalable cell therapy manufacturing.
• Increased interest in longevity research drives more funding and partnerships in biotech.

What critics are saying

• Regulatory scrutiny on anti-aging therapies could delay clinical trials and approvals.
• New competitors like Altos Labs could impact Retro Biosciences' market share.
• Reliance on Multiply Labs' systems poses risks if technological failures occur.

What makes Retro Biosciences unique

• Retro Biosciences targets cellular mechanisms of aging to extend lifespan by ten years.
• The company employs a diversified model with cellular reprogramming, plasma therapy, and autophagy.
• Retro Biosciences leverages advanced technologies like single-cell multi-omics and computational biology.

Help us improve and share your feedback! Did you find this helpful?

YesNo